입자선 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료 유형별, 시스템별, 용도별, 암 유형별, 지역별, 부문별 예측(2024-2030년)

Particle Therapy Market Growth & Trends:

The global particle therapy market size is anticipated to reach USD 2.55 billion by 2030, registering a CAGR of 7.63% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of cancer aided by the growing geriatric population. Any age can acquire the disease, but as people age, their chances of developing the disease increase significantly. According to GLOBOCAN 2022 data, approximately 53% of cancer patients were aged 65 years or older. This correlation is probably caused by less efficient cellular repair processes and the build-up of risk factors for particular malignancies, which rise with age.

Therefore, to ensure that older adults are not left behind in the pursuit of universal health coverage, governments will need to devise a plan to promote change for older adults with cancer. Increasing government support for cancer patients and their caregivers for treatment completion fuels the market's growth. For instance, in April 2024, the Albanese Government offered USD 16.5 for a Cancer Support Program grant, with the first round now open for application. This program will enhance disease outcomes for individuals all across Australia. The funding is intended to support small national organizations that promote treatment. Furthermore, the Union for International Cancer Control (UICC) celebrates 4th February as "World Cancer Day" every year to raise awareness about cancer and available options for treatment.

Such initiatives are expected to drive demand for particle beam treatment over the forecast period, driving market growth. Technological advancements in computing have resulted in faster, more intelligent, & more capable treatment planning and have enabled constant imaging guidance, more precise dosing, and delivery of higher doses. This has resulted in greater efficiency & fewer adverse effects. Dosage optimization and treatment planning have become easier owing to advanced computer algorithms. The advent of proton radiation therapy has helped overcome problems due to the movement of patients, such as during breathing. Furthermore, advances in laser technology enable the development of ultra-quick double-light pulses that can interact with the subatomic process, which helps in tracking ultrafast intra-atom motion using synchrotron radiation.

Moreover, the growing launch of disease diagnosis and treatment centers drives demand for products during the forecast period. For instance, in February 2023, the Apollo Proton Cancer Center launched a Proton Gantry named "Dr. APJ Abdul Kalam Therapy Bay" to offer the most advanced and comprehensive cancer care in India. The hospital administers the nation's largest Proton Beam Therapy (PBT) program to treat patients. APCC is the first and only proton therapy center in the Middle East and South Asia.

Particle Therapy Market Report Highlights:

• The proton therapy segment held the largest share in 2023 due to the disease's high treatment rate, decreased side effects, high treatment adherence rate, and growing prevalence
• The single-room systems segment is expected to grow at the fastest CAGR during the forecast period due to its advantages over multi-room systems, such as low cost, and increased adoption by smaller hospitals and facilities
• The treatment segment held the largest share in 2023 due to hospital treatment rates, patient preference for particle therapy over other methods, and an increasing number of patients visiting hospitals for treatment
• The pediatric cancer segment held the largest in 2023 owing to a rise in the prevalence and incidence of the disease worldwide and rising demand for particle therapy for its treatment
• North America dominated the global market in 2023 owing to factors advanced healthcare infrastructure, high disease prevalence, and a favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy Type
  • 1.2.2. System
  • 1.2.3. Application
  • 1.2.4. Cancer Type
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapy type and system Outlook
  • 2.2.2. Application and cancer type outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Particle Therapy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of cancer
    • 3.2.1.2. Increasing awareness about benefits of particle therapy
    • 3.2.1.3. Rising geriatric population
    • 3.2.1.4. Technological advancements in particle therapy
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of skilled radiotherapy professionals
    • 3.2.2.2. Stringent regulatory policies
    • 3.2.2.3. Adverse effects of particle therapy
• 3.3. Particle Therapy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Particle Therapy Market: Therapy Estimates & Trend Analysis

• 4.1. Global Particle Therapy Market: Therapy Type Dashboard
• 4.2. Global Particle Therapy Market: Therapy Type Movement Analysis
• 4.3. Global Particle Therapy Market By Therapy Type, Revenue
• 4.4. Proton Therapy
  • 4.4.1. Proton Therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Heavy Ion Therapy
  • 4.5.1. Heavy Ion Therapy market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Particle Therapy Market: System Estimates & Trend Analysis

• 5.1. Global Particle Therapy Market: System Dashboard
• 5.2. Global Particle Therapy Market: System Movement Analysis
• 5.3. Global Particle Therapy Market By System, Revenue
• 5.4. Single Room Systems
  • 5.4.1. Single room systems market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Multi-room Systems
  • 5.5.1. Multi-room systems market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Particle Therapy Market: Application Estimates & Trend Analysis

• 6.1. Global Particle Therapy Market: Application Dashboard
• 6.2. Global Particle Therapy Market: Application Movement Analysis
• 6.3. Global Particle Therapy Market By Application, Revenue
• 6.4. Treatment
  • 6.4.1. Treatment market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Research
  • 6.5.1. Clinical research market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Particle Therapy Market: Cancer Type Estimates & Trend Analysis

• 7.1. Global Particle Therapy Market: Cancer Type Dashboard
• 7.2. Global Particle Therapy Market: Cancer Type Movement Analysis
• 7.3. Global Particle Therapy Market By Cancer Type, Revenue
• 7.4. Pediatric Cancer
  • 7.4.1. Pediatric cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Breast Cancer
  • 7.5.1. Breast Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Lung Cancer
  • 7.6.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Head and Neck Cancer
  • 7.7.1. Head and neck cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Others
  • 7.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Particle Therapy Market: Regional Estimates & Trend Analysis By Therapy Type, System, and Application

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Mexico
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Participant Overview
• 9.3. Financial Overview
• 9.4. Product Benchmarking
• 9.5. Company Market Share Analysis, 2023
• 9.6. Strategy Mapping
• 9.7. Company Profiles
  • 9.7.1. IBA Worldwide.
    • 9.7.1.1. Company overview
    • 9.7.1.2. Financial performance
    • 9.7.1.3. benchmarking
    • 9.7.1.4. Strategic initiatives
  • 9.7.2. Siemens Healthcare GmbH (Varian Medical Systems, Inc.)
    • 9.7.2.1. Company overview
    • 9.7.2.2. Financial performance
    • 9.7.2.3. benchmarking
    • 9.7.2.4. Strategic initiatives
  • 9.7.3. Hitachi Ltd
    • 9.7.3.1. Company overview
    • 9.7.3.2. Financial performance
    • 9.7.3.3. benchmarking
    • 9.7.3.4. Strategic initiatives
  • 9.7.4. Mevion Medical Systems.
    • 9.7.4.1. Company overview
    • 9.7.4.2. Financial performance
    • 9.7.4.3. benchmarking
    • 9.7.4.4. Strategic initiatives
  • 9.7.5. Provision Healthcare.
    • 9.7.5.1. Company overview
    • 9.7.5.2. Financial performance
    • 9.7.5.3. benchmarking
    • 9.7.5.4. Strategic initiatives
  • 9.7.6. Optivus Proton Therapy, Inc.
    • 9.7.6.1. Company overview
    • 9.7.6.2. Financial performance
    • 9.7.6.3. benchmarking
    • 9.7.6.4. Strategic initiatives
  • 9.7.7. Sumitomo Heavy Industries, Ltd.
    • 9.7.7.1. Company overview
    • 9.7.7.2. Financial performance
    • 9.7.7.3. benchmarking
    • 9.7.7.4. Strategic initiatives
  • 9.7.8. ProTom International.
    • 9.7.8.1. Company overview
    • 9.7.8.2. Financial performance
    • 9.7.8.3. benchmarking
    • 9.7.8.4. Strategic initiatives
  • 9.7.9. B dot Medical Inc.
    • 9.7.9.1. Company overview
    • 9.7.9.2. Financial performance
    • 9.7.9.3. benchmarking
    • 9.7.9.4. Strategic initiatives
  • 9.7.10. LeyBold.
    • 9.7.10.1. Company overview
    • 9.7.10.2. Financial performance
    • 9.7.10.3. benchmarking
    • 9.7.10.4. Strategic initiatives
  • 9.7.11. Advanced Oncotherapy Plc.
    • 9.7.11.1. Company overview
    • 9.7.11.2. Financial performance
    • 9.7.11.3. benchmarking
    • 9.7.11.4. Strategic initiatives